

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2024 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting an administrative supplement in scope of the parent award for one eligible grant recipient funded under the FY 2023 Provider's Clinical Support System—Medications for Opioid Use Disorder (PCSS–MOUD), Notice of Funding Opportunity (NOFO) TI–23–014. The recipient may receive up to \$1,000,000. This supplement provides support to the recipient with a project end date of September 30, 2025. The supplemental funding will be used to support increased fees from the training platform service as a result of an increase in the number of practitioners accessing training from the program.

FOR FURTHER INFORMATION CONTACT: Patti Juliana, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, telephone 240–276–1195; email: patti.juliana@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

Funding Opportunity Title: FY2024 Providers' Clinical Support System—Medications for Opioid Use Disorder (PCSS–MOUD) TI–23–014.

Assistance Listing Number: 93.243.

Authority: Section 509 of the of the Public Health Service Act.

Justification: The one SAMHSA-funded grant recipient of this NOFO has experienced increased fees from its training platform service as a result of an increase in the number of practitioners accessing training from the program.

This is not a formal request for application. Assistance will only be provided to the one PCSS–MOUD grant recipient funded in FY 2023 under the Providers' Clinical Support System—Medications for Opioid Use Disorder (PCSS–MOUD) [TI–23–014] based on the receipt of a satisfactory application and associated budget that is approved by a review group.

Dated: August 20, 2024.

Ann Ferrero,

Public Health Analyst.

[FR Doc. 2024–19021 Filed 8–23–24; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2024 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting administrative supplements in scope of the parent award for the 26 eligible grant recipients funded in FY 2022 under the First Responders-Comprehensive Addiction and Recovery Act (FR–CARA), Notice of Funding Opportunity (NOFO) TI–22–008. Recipients may receive up to \$58,190 each, for a total of \$1,512,940 across the program. These recipients have a project end date for use of these supplemental funds of September 29, 2025. The supplements will be used to fund a Training of Trainer (ToT) model to rapidly expand workforce development and capacity in the arena of preventing overdose related deaths and adverse events within existing projects funded under the FR–CARA program.

FOR FURTHER INFORMATION CONTACT:

Shannon Hastings, NOFO Lead, Division of Targeted Prevention, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, *DTP-NOFO@samhsa.hhs.gov*, Telephone: (240) 276–1869.

SUPPLEMENTARY INFORMATION:

Funding Opportunity Title: FY 2022 First Responders-Comprehensive Addiction and Recovery Act (FR–CARA) TI–22–008.

Assistance Listing Number: 93.243.

Authority: Section 546 of the Public Health Service Act, as amended, 42 U.S.C. 290ee–1.

Justification: These supplement awards will be offered to the FY 2022 cohorts under TI–22–008. Supplemental funding will be awarded to this cohort that has two years remaining in awards

to implement their projects. FY 2022 cohorts have implemented existing activities well positioned to be leveraged under the ToT model. These factors will benefit SAMHSA so that the agency will be able to track the effects of the ToT model over time. This work aligns with SAMHSA's goals of expanding access to naloxone and other opioid overdose reversal medications and enhances SAMHSA's naloxone saturation and overdose prevention efforts.

This is not a formal request for application. Assistance will only be provided to the 26 FR–CARA grant recipients funded in FY 2022 under the First Responders-Comprehensive Addiction and Recovery Act NOFO (TI–22–008) based on the receipt of a satisfactory application and associated budget that is approved by a review group.

Dated: August 20, 2024.

Ann Ferrero,

Public Health Analyst.

[FR Doc. 2024–18944 Filed 8–23–24; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 2024 Notice of Supplemental Funding Opportunity

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services (HHS).

ACTION: Notice of intent to award supplemental funding.

SUMMARY: This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting administrative supplements in scope of the parent award for the five eligible grant recipients funded in FY22 and FY23 under the Grants to Prevent Prescription Drug/Opioid Overdose Program (PDO), Notice of Funding Opportunity (NOFO) SP–21–002. Recipients may receive up to \$279,266 each for a total of \$1,396,330 across the program. These recipients have a project end date for use of these supplemental funds of September 29, 2025. The supplemental funding will be used to fund a comprehensive Training of Trainer (ToT) model to enhance workforce development and capacity in the arena of preventing prescription drug/overdose related deaths and adverse